StockData
Certara, Inc. logo

Certara, Inc. (CERT) company profile

CERTNasdaqServices-Prepackaged SoftwareFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3017% below fair value
$11.90+0.17 (+1.45%)

Close on Nov 12, 2026Market cap $1.82BP/E –Yield –

About Certara

Services-Prepackaged Software, SIC 7372

Certara provides biosimulation software and technology-enabled consulting services to support model-informed drug development. Its primary solutions include mechanistic and empirical biosimulation platforms, scientific informatics, preclinical and clinical data automation tools, and regulatory science software. These offerings help clients design clinical trials, standardize research data, predict drug effects, and streamline regulatory submissions. The company serves biopharmaceutical and biotechnology companies, contract research organizations, academic institutions, and government bodies, alongside customers in animal health, crop science, and medical devices.

The company operates globally, with its software licensed across seventy countries and utilized by twenty global regulatory agencies. As of year-end 2025, it employs over 1,500 professionals across twenty-eight countries, including the United States, Europe, and Asia. The provided text does not identify the location of its corporate headquarters.

Summary of the business section of Certara's latest annual report, written by StockData.

Company profile

Company

Legal name
Certara, Inc.
Headquarters
Radnor, PA
Address
4 Radnor Corporate Center, Suite 350 19087
Phone
(415) 237-8272
Employees
41, Dec 31, 2025
Industry
Services-Prepackaged Software
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
RSM US LLP, Blue Bell, Pennsylvania

Stock & identifiers

Ticker
CERT
Exchange
Nasdaq
IPO date
Dec 14, 2020
Shares outstanding
153M, Aug 1, 2026
Public float
$1.40B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1827090
CUSIP
15687V109
ISIN
US15687V1098
FIGI
BBG00Y7BR4K3
Share class FIGI
BBG00Y7BR4L2
LEI
549300LI8UBB8QGWZ814
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
John V. W. ReyndersChief Financial Officer, Director26,466
Jon Matthew ResnickChief Executive Officer, Director59,766
William F. FeeheryCHIEF EXECUTIVE OFFICER, Director2,360,769
Faiz MohammedInterim CFO163,686
Rona AnhaltChief Human Resources Officer19,030
Daniel CorcoranSVP and General Counsel39,939
John E. GallagherChief Financial Officer62,099
Robert AspburyPRESIDENT, PREDICTIVE TECH321,686
Leif E. PedersenPRESIDENT, CHIEF COMMERCAL OFF84,955
Adrian McKemeyPresident, Drug Dev. Solutions8,207
Eran BroshyDirector50,708
James E. Cashman IiiDirector484,197
Cynthia CollinsDirector51,846
Rosemary A. CraneDirector45,672
Matthew M. WalshDirector213,316
Arjun BediDirector5,547
Nancy KilleferDirector51,846

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.49M$1.77M$2.12M$26$78
FY2024$7.22M$2.04M$2.31M$28$83
FY2023$7.81M$4.40M$2.21M$46$80
FY2022$6.23M-$4.57M$1.91M$42$82
FY2021$6.24M$2.33M$2.03M$75$117
FY2020$3.63M$71.87M$1.84M$89$104

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
William F. Feehery
Former Chief Executive Officer
$795.68K–$4.93M$747.94K$20.28K$6.49M-10%
John E. Gallagher III
Senior Vice President and CFO
$606.32K–$1.80M$301.04K$16.89K$2.72M-8%
Robert A. Aspbury
President, Certara Predictive Technologies
$457.67K–$1.20M$331.39K$37.07K$2.03M+0%
Leif E. Pedersen
President, Chief Commercial Officer
$458.35K–$1.20M$214.99K$16.74K$1.89M-8%
Adrian K. McKemey
President, Certara Drug Development Solutions
$366.67K$466.00K$856.96K$161.17K$5.03K$1.86M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 14, 2020
Offer price
$23.00
Securities offered
29,055,000
Gross proceeds
$668.27M
Exchange
Nasdaq
First trading day
Dec 11, 2020
First-day close
$38.08+65.6%
Lock-up ends (est.)
Jun 9, 2021

“The initial public offering price of our common stock is $23.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Table of Contents unavailability of critical data and confidential or proprietary information (our own or that of third parties, including information about our customers and employees) and the disruption of business operations. … In addition, our collection, use, disclosure, protection and other processing of information is subject to related contractual requirements. Compliance with such laws and related contractual requirements may require changes to our information processing practices and m”

Corporate history

Events identified from SEC filings

See a number that looks wrong?